Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL

被引：25
作者：
Tripodi, Armando [1 ,2 ]
Di Iorio, Giancarlo [3 ]
Lippi, Giuseppe [4 ]
Testa, Sophie [5 ]
Manotti, Cesare [6 ]
机构：
[1] Univ Milan, Milan, Italy
[2] IRCCS Ca Granda Maggiore Hosp Fdn, Dept Clin Sci & Community Hlth, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy
[3] Gen Hosp, Anticoagulat Serv, Clin Chem Lab, Pescara, Italy
[4] Acad Hosp, Dept Pathol & Lab Med, Lab Clin Chem & Hematol, Parma, Italy
[5] Gen Hosp, Ctr Thrombosis & Hemostasis, Cremona, Italy
[6] Anticoagulat Serv, Fidenza, Italy
来源：
CLINICAL CHEMISTRY AND LABORATORY MEDICINE | 2012年 / 50卷 / 12期
关键词：
anticoagulation; new oral anticoagulants; thrombosis; warfarin; DIRECT THROMBIN INHIBITOR; COAGULATION ASSAYS; DABIGATRAN ETEXILATE; RIVAROXABAN; REVERSAL; INTERFERENCE;
D O I：
10.1515/cclm-2012-0327
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
At variance with vitamin K antagonists, the new oral anticoagulants (NOAs) can be prescribed at fixed dosage without adjustment by laboratory testing. However, this does not necessarily mean that the laboratory does not play a role for their management. This position paper represents the consensus document of three Italian scientific societies dealing with laboratory issues in thrombosis and hemostasis. It is aimed at reviewing: 1) which test(s) should be used to evaluate the anticoagulant effect of each of the NOAs presently available (i.e., dabigatran, rivaroxaban and apixaban); 2) the patients to be investigated; and 3) the timing of investigation.
引用
收藏
页码：2137 / 2140
页数：4
相关论文
共 25 条
  • [1] Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    Ageno, Walter
    Gallus, Alexander S.
    Wittkowsky, Ann
    Crowther, Mark
    Hylek, Elaine M.
    Palareti, Gualtiero
    [J]. CHEST, 2012, 141 (02) : E44S - E88S
  • [2] Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
    Barrett, Yu Chen
    Wang, Zhaoqing
    Frost, Charles
    Shenker, Andrew
    [J]. THROMBOSIS AND HAEMOSTASIS, 2010, 104 (06) : 1263 - 1271
  • [3] Impact of dabigatran on a large panel of routine or specific coagulation assays Laboratory recommendations for monitoring of dabigatran etexilate
    Douxfils, Jonathan
    Mullier, Francois
    Robert, Severine
    Chatelain, Christian
    Chatelain, Bernard
    Dogne, Jean-Michel
    [J]. THROMBOSIS AND HAEMOSTASIS, 2012, 107 (05) : 985 - 997
  • [4] Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
    Eerenberg, Elise S.
    Kamphuisen, Pieter W.
    Sijpkens, Meertien K.
    Meijers, Joost C.
    Buller, Harry R.
    Levi, Marcel
    [J]. CIRCULATION, 2011, 124 (14) : 1573 - 1579
  • [5] Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?
    Favaloro, Emmanuel J.
    Lippi, Giuseppe
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (05) : 755 - 757
  • [6] Laboratory reporting of hemostasis assays: the final post-analytical opportunity to reduce errors of clinical diagnosis in hemostasis?
    Favaloro, Emmanuel J.
    Lippi, Giuseppe
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2010, 48 (03) : 309 - 321
  • [7] Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests
    Halbmayer, Walter-Michael
    Weigel, Guenter
    Quehenberger, Peter
    Tomasits, Josef
    Haushofer, Alexander C.
    Aspoeck, Gerold
    Loacker, Lorin
    Schnapka-Koepf, Mirjam
    Goebel, Georg
    Griesmacher, Andrea
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (09) : 1601 - 1605
  • [8] Determination of Rivaroxaban in Human Plasma Samples
    Harenberg, Job
    Erdle, Sandra
    Marx, Svetlana
    Kraemer, Roland
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2012, 38 (02) : 178 - 184
  • [9] Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
    Hillarp, A.
    Baghaei, F.
    Blixter, I. Fagerberg
    Gustafsson, K. M.
    Stigendal, L.
    Sten-Linder, M.
    Strandberg, K.
    Lindahl, T. L.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (01) : 133 - 139
  • [10] Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors
    Kaatz, Scott
    Kouides, Peter A.
    Garcia, David A.
    Spyropolous, Alex C.
    Crowther, Mark
    Douketis, Jim D.
    Chan, Anthony K. C.
    James, Andra
    Moll, Stephan
    Ortel, Thomas L.
    Van Cott, Elizabeth M.
    Ansell, Jack
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 : S141 - S145
123